Skip to main content
TipRanks
Go Ultimate75% OFF

Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H (3378) Income Statement

Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H Income Statement

Last quarter (Q2 2019), Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H's total revenue was ¥3.48B, an increase of 7.82% from the same quarter last year. In Q2, Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H's net income was ¥167.19M. See Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H’s key income statements, including revenue, expenses, profit, and income.

Income Statement
Income StatementDec 21Dec 20Dec 19Dec 18Dec 17
¥ 25.69B¥ 17.69B¥ 13.93B¥ 12.92B¥ 12.92B
¥ 1.38B¥ 1.23B¥ 1.26B¥ 1.22B¥ 1.20B
¥ 307.29M¥ 229.45M¥ 221.13M¥ 223.22M¥ 257.54M
Depreciation and Amortization¥ 0.00¥ 794.25M¥ 764.71M¥ 697.51M¥ 595.20M
¥ 1.29B¥ 1.90B¥ 1.91B¥ 1.51B¥ 1.45B
¥ 1.20B¥ 770.54M¥ 759.37M¥ 809.02M¥ 855.84M
¥ -217.41M¥ 56.58M¥ 141.55M¥ 562.00K¥ 214.80M
¥ 983.82M¥ 827.12M¥ 900.92M¥ 809.59M¥ 1.07B
¥ 769.11M¥ 616.58M¥ 668.76M¥ 554.39M¥ 819.60M
Per Share Metrics
Basic EPS¥ 0.28¥ 0.23¥ 0.25¥ 0.20¥ 0.30
Diluted EPS¥ 0.28¥ 0.23¥ 0.25¥ 0.20¥ 0.30
Weighted Average Shares Outstanding2.73B2.73B2.73B2.73B2.73B
Weighted Average Shares Outstanding (Diluted)2.73B2.73B2.73B2.73B2.73B

Currency in CNY

Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H Earnings and Revenue History

010B20B30B2 %4 %6 %8 %EarningsProfit Margin20172018201920202021RevenueEarningsProfit Margin